The company's customer base spans universities, hospitals, and specialized laboratories
On February 12, 2026, Bio-Rad Laboratories — a $2.6 billion pillar of the global life sciences and diagnostics world — will draw back the curtain on its 2025 fiscal year, offering investors and analysts a reckoning with how one of science's quiet enablers fared through another year of industry evolution. The Hercules, California company, whose tools serve everyone from university researchers to hospital laboratories, will host a live management call that evening, inviting the world to listen as numbers become narrative. In the rhythm of quarterly disclosure, such moments remind us that even the infrastructure of human health must answer to the ledger.
- A $2.6 billion life sciences company is about to reveal whether 2025 rewarded or tested its ambitions across research and clinical diagnostics markets.
- Analysts tracking the broader life sciences sector will be watching closely, as Bio-Rad's results could signal wider industry trends in diagnostics and biopharmaceutical services.
- The company has mapped out a clear path for investor access — phone dial-ins, a live webcast, and a supplemental presentation — signaling a deliberate effort at transparency.
- A one-year replay archive ensures that Bio-Rad's story reaches global stakeholders regardless of time zone, reflecting how investor relations has become a discipline of inclusion as much as disclosure.
Bio-Rad Laboratories will release its fourth-quarter and full-year 2025 financial results after markets close on February 12, 2026, followed that evening by a management conference call at 5 p.m. Eastern Time. The Hercules, California company — listed on the NYSE under BIO and BIO.B — gives investors a direct line to leadership on the day numbers become public.
With roughly 7,500 employees and $2.6 billion in 2024 revenue, Bio-Rad operates across research and clinical diagnostics, serving universities, hospital systems, biopharmaceutical manufacturers, and specialized labs focused on food safety and environmental testing. Its reach is genuinely global, spanning research, development, manufacturing, and sales operations worldwide.
Investors can join the call by phone or stream it live through the "Events & Presentations" section at investors.bio-rad.com, where a supplemental earnings presentation will also be available. For those unable to attend live, a webcast recording will remain accessible for up to one year — a now-standard accommodation for audiences spread across time zones.
The announcement arrives at a meaningful moment, as Bio-Rad continues to compete in a life sciences landscape that saw notable shifts throughout 2025. How the company's performance measures against expectations will draw scrutiny from analysts watching the sector's broader trajectory.
Bio-Rad Laboratories will open its books on the 2025 fiscal year when it releases fourth-quarter and full-year financial results after the market closes on Thursday, February 12, 2026. The Hercules, California-based diagnostics and life science company will follow the earnings announcement with a management conference call at 5 p.m. Eastern Time that same day, giving investors a chance to hear directly from leadership about the year's performance.
The company, which trades on the New York Stock Exchange under the ticker symbols BIO and BIO.B, operates across both the research and clinical diagnostics sectors. With roughly 7,500 employees spread across a global network of research, development, manufacturing, and sales operations, Bio-Rad generated $2.6 billion in revenue during 2024. The company's customer base spans universities and academic research institutions, hospital systems, biopharmaceutical manufacturers, and specialized laboratories focused on clinical work, food safety, and environmental quality testing.
Investors interested in participating in the live conference call can dial into the discussion using one of two phone numbers: (800) 715-9871 for callers within the United States, or (646) 307-1963 for those calling from outside the country. The access code for the call is 9562470. For those who prefer not to dial in, Bio-Rad will stream the call live on its investor relations website, accessible through the "Events & Presentations" section at investors.bio-rad.com. The company will also provide a supplemental earnings presentation alongside the webcast, offering additional context for the financial figures being discussed.
One of the practical advantages for busy investors is that Bio-Rad will maintain a recording of the webcast for up to one year following the call, allowing those who cannot tune in live to review the discussion and presentation materials at their convenience. This archive approach has become standard practice among major public companies, recognizing that global audiences operate across different time zones and schedules.
The earnings announcement arrives as Bio-Rad continues to navigate a competitive landscape in life sciences and diagnostics. The company positions itself as an innovator in developing and manufacturing products that serve both the research community and clinical laboratories worldwide. How the company performed against expectations during 2025—a year that saw continued evolution in the diagnostics and research sectors—will likely draw attention from analysts tracking the broader life sciences industry.
The Hearth Conversation Another angle on the story
Why does a company like Bio-Rad bother with a formal earnings call when they could just release the numbers?
Because investors want to hear the story behind the numbers. A conference call lets management explain what drove growth or headwinds, what they're seeing in different markets, what's coming next. It's the difference between a spreadsheet and a conversation.
Who actually listens to these calls?
Institutional investors, hedge funds, equity analysts who cover the company, and individual shareholders with significant stakes. The call gets recorded, so people can listen later if they miss it live. It's become part of the ritual of being a public company.
What would make this particular earnings call noteworthy?
If Bio-Rad's revenue growth accelerated or decelerated sharply. If they're gaining or losing market share in diagnostics. If they're investing heavily in new product lines or facing supply chain issues. The numbers will tell one story; the tone and forward guidance will tell another.
Does the fact that they have two share classes—BIO and BIO.B—matter for this announcement?
It matters for voting control and ownership structure, but both classes will hear the same financial results and outlook. The dual-class structure is a governance choice, not something that changes what gets reported.
Why give a year-long replay window?
Accessibility and liability protection. Some investors will want to review the call weeks later when they're making decisions. And having a permanent record means there's no ambiguity about what management said—everything's documented.